Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 11Completed 6Unknown 4Terminated 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1

Conditions

Recurrence 1Multiple Myeloma 1Genetic Diseases, Inborn 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × Clinical Trials, Phase II as Topic × Clear all
NCT03683277 2025-02-19

IFM2014-01

Intergroupe Francophone du Myelome

Phase 2 Terminated
26 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Genetic Diseases, Inborn

NCT02382406 2023-05-23

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Hoosier Cancer Research Network

Phase 1/2 Terminated
46 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡